As part of its End-To-End Platform, Medigene discovers natural TCR sequences with high specificity, sensitivity and safety (3S). These optimal 3S TCRs can subsequently be merged with a Cluster of ...

has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline. The collaboration was first launched in 2013, and is based around Immunocore’s T Cell Receptor (TCR ...

Medigene continuously strengthens and expands its patent portfolio by developing new 3S TCRs, integrating advanced technologies, and extending its existing patents to new regions. The Company now owns ...

Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...

Marcello Lotti has reiterated the stance of WSC Group regarding TCR cars competing in ‘unlicensed events’ by confirming that an entry into such an event will result in a car losing its official ...

The deal – which included an upfront payment of around $50 million and focused on the development of a pair of autologous and/or allogeneic T-cell receptor (TCR) based therapies – will come to ...

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates ...

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal ...

A new TCR series in Panama will launch later this month after a six-year agreement was signed to introduce the regulations into the county. Autódromo Panamá has signed terms with WSC Group that will ...

Jonathan D. Schoenfeld; Nilofer S. Azad; Jacob Gross; Li Chen; Michael J. Overman; Katrina Kao; Latifa Jackson; Donna Brunnquell; Xiangning Bu; Christina Coppola ...

Clinical trials related to TCR-T cell therapy and monoclonal antibodies designed for overcoming immunosuppression, and recent advances made in understanding how TCRs are additionally examined. New ...